X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims for the clinical development of NephroDI’s asset, NDI-5001, a novel kidney-targeted small molecule AMPK activator, as a potential therapy for X-linked congenital Nephrogenic Diabetes Insipidus (NDI).
Lead Product(s): NDI-5001
Therapeutic Area: Rare Diseases and Disorders Product Name: NDI-5001
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: NephroDI Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2023
Details:
The agreement aims to evaluate IRLAB’s neuropsychiatric programs IRL757 and IRL942. Drug candidate IRL757 is being developed as a treatment for apathy in neurological disorders such as Parkinson’s, Alzheimer’s disease with a once-daily oral administration.
Lead Product(s): IRL757
Therapeutic Area: Psychiatry/Psychology Product Name: IRL757
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: IRLAB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 16, 2023
Details:
Under the terms of the agreement, MSRD and Sentinel will collaborate to support the Phase 1a and Phase 1b clinical trials for Sentinel’s investigational compound SOL784 with the opportunity to expand the collaboration after those studies.
Lead Product(s): SOL784
Therapeutic Area: Genetic Disease Product Name: SOL784
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sentinel Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 03, 2021
Details:
Under the terms of the agreement, MSRD and Aché will collaborate to advance Aché’s novel compound ACH000029 through phase 1b clinical trials with the opportunity to expand the collaboration after those studies.
Lead Product(s): ACH000029
Therapeutic Area: Psychiatry/Psychology Product Name: ACH000029
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Ache Laboratorios Farmaceuticos SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 24, 2021
Details:
Under the terms of the agreement, MSRD and Eikonizo will collaborate to advance Eikonizo’s HDAC6 inhibitors through preclinical and Phase 1b clinical studies respectively, with the opportunity to expand the collaboration after those studies.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eikonizo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 09, 2021
Details:
Activities will support the clinical development of Rugen’s potential first-in-class, orally administered drug candidate with initial clinical focus on treatment-resistant depression.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rugen Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
